Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1806 2
1807 2
1808 1
1810 1
1811 1
1812 1
1813 1
1815 1
1817 1
1821 1
1826 1
1829 1
1830 1
1832 3
1833 1
1838 3
1839 1
1840 1
1841 2
1842 2
1843 1
1845 3
1846 3
1847 2
1848 5
1849 2
1850 2
1851 7
1852 5
1853 3
1854 3
1855 7
1856 4
1857 3
1859 2
1860 6
1861 2
1862 1
1863 2
1864 4
1865 1
1866 3
1867 5
1868 1
1869 2
1870 2
1871 4
1872 2
1873 4
1874 2
1875 4
1876 1
1877 5
1878 1
1879 4
1880 6
1881 7
1882 10
1883 7
1884 7
1885 4
1886 4
1887 11
1888 10
1889 11
1890 4
1891 5
1892 7
1893 7
1894 2
1895 8
1896 8
1897 6
1898 11
1899 10
1900 5
1901 7
1902 3
1903 6
1904 6
1905 9
1906 19
1907 24
1908 11
1909 22
1910 12
1911 19
1912 13
1913 20
1914 11
1915 20
1916 17
1917 18
1918 15
1919 16
1920 31
1921 14
1922 15
1923 18
1924 17
1925 15
1926 26
1927 32
1928 39
1929 26
1930 29
1931 30
1932 29
1933 22
1934 21
1935 29
1936 17
1937 21
1938 17
1939 13
1940 11
1941 12
1942 10
1943 7
1944 8
1945 71
1946 178
1947 207
1948 208
1949 191
1950 230
1951 316
1952 300
1953 275
1954 276
1955 263
1956 300
1957 321
1958 295
1959 326
1960 339
1961 388
1962 474
1963 682
1964 697
1965 674
1966 663
1967 655
1968 828
1969 861
1970 897
1971 1070
1972 1189
1973 1210
1974 1363
1975 3499
1976 3736
1977 3692
1978 3660
1979 4593
1980 5717
1981 6001
1982 6232
1983 7280
1984 7915
1985 8369
1986 8537
1987 8949
1988 9428
1989 11408
1990 11744
1991 11949
1992 12832
1993 14391
1994 14994
1995 15653
1996 16256
1997 16540
1998 17774
1999 18927
2000 20519
2001 21372
2002 22350
2003 24421
2004 26315
2005 29117
2006 31546
2007 33572
2008 36411
2009 38340
2010 41350
2011 45188
2012 49118
2013 52004
2014 55404
2015 58472
2016 60972
2017 63171
2018 67366
2019 72376
2020 83799
2021 92751
2022 91213
2023 87807
2024 35962

Text availability

Article attribute

Article type

Publication date

Search Results

1,361,044 results

Results by year

Filters applied: . Clear all
Page 1
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
Kopmar NE, Quach K, Gooley TA, Martino CH, Cherian S, Percival MM, Halpern AB, Ghiuzeli CM, Oehler VG, Abkowitz JL, Walter RB, Cassaday RD. Kopmar NE, et al. JAMA Oncol. 2024 May 9. doi: 10.1001/jamaoncol.2024.0967. Online ahead of print. JAMA Oncol. 2024. PMID: 38722664
MAIN OUTCOMES AND MEASURES: The primary outcome was the maximum tolerated dose of InO when combined with DA-EPOCH, defined as the highest dose level that produced a rate of dose-limiting toxicity below 33%. Secondary objectives included response rates, survival estimates, …
MAIN OUTCOMES AND MEASURES: The primary outcome was the maximum tolerated dose of InO when combined with DA-EPOCH, defined as the highest do …
Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.
Fu DJ, Bagga P, Naik G, Glinton S, Faes L, Liefers B, Lima R, Wignall G, Keane PA, Ioannidou E, Ribeiro Reis AP, McKeown A, Scheibler L, Patel PJ, Moghul I, Pontikos N, Balaskas K. Fu DJ, et al. JAMA Ophthalmol. 2024 May 9. doi: 10.1001/jamaophthalmol.2024.1269. Online ahead of print. JAMA Ophthalmol. 2024. PMID: 38722644
DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of 11 614 SD-OCT volumes from 936 of the 1258 participants in 2 parallel phase 3 studies, the Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic At …
DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc analysis of 11 614 SD-OCT volumes from 936 of the 1258 participants in 2 parallel pha …
In Vivo Reactive Astrocyte Imaging in Patients With Schizophrenia Using Fluorine 18-Labeled THK5351.
Kim M, Choi W, Choi S, Oh H, Kim J, Lee J, An SJ, Hwang JS, Lee YS, Song IC, Moon SY, Lho SK, Cho SS, Kwon JS. Kim M, et al. JAMA Netw Open. 2024 May 1;7(5):e2410684. doi: 10.1001/jamanetworkopen.2024.10684. JAMA Netw Open. 2024. PMID: 38722627
MAIN OUTCOMES AND MEASURES: Standardized uptake value ratios (SUVrs) of [18F]THK5351 in the anterior cingulate cortex (ACC) and hippocampus as primary regions of interest (ROIs), with other limbic regions as secondary ROIs, and the correlation between altered SUVrs and Pos …
MAIN OUTCOMES AND MEASURES: Standardized uptake value ratios (SUVrs) of [18F]THK5351 in the anterior cingulate cortex (ACC) and hippocampus …
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, Gómez-Almaguer D, Baer MR, Gambacorti-Passerini C, McCloskey J, Minami Y, Papayannidis C, Rocha V, Rousselot P, Vachhani P, Wang ES, Wang B, Hennessy M, Vorog A, Patel N, Yeh T, Ribera JM. Jabbour E, et al. JAMA. 2024 May 9. doi: 10.1001/jama.2024.4783. Online ahead of print. JAMA. 2024. PMID: 38722621
MAIN OUTCOMES AND MEASURES: The primary end point of this interim analysis was MRD-negative complete remission (0.01% BCR::ABL1 [MR4] centrally assessed by reverse transcriptase-quantitative polymerase chain reaction), with complete remission maintained for at least 4 weeks at th …
MAIN OUTCOMES AND MEASURES: The primary end point of this interim analysis was MRD-negative complete remission (0.01% BCR::ABL1 [MR4] centra …
MDPV (3,4-methylenedioxypyrovalerone) administered to mice during development of the central nervous system produces persistent learning and memory impairments.
Kuczyńska K, Bartkowska K, Djavadian R, Zwierzyńska E, Wojcieszak J. Kuczyńska K, et al. Pharmacol Rep. 2024 May 9. doi: 10.1007/s43440-024-00599-0. Online ahead of print. Pharmacol Rep. 2024. PMID: 38722542
BACKGROUND: Synthetic cathinones (SC) constitute the second most frequently abused class of new psychoactive substances. ...Here, we examined the effects of repeated exposure of mice during infancy, to 3,4-methylenedioxypyrovalerone (MDPV), a SC potently enhancing d …
BACKGROUND: Synthetic cathinones (SC) constitute the second most frequently abused class of new psychoactive substances. ...Here, we …
Is young adult idiopathic scoliosis a distinct clinical entity from adolescent idiopathic scoliosis? a Systematic Review and Meta-analysis comparing pre-operative characteristics and operative outcomes.
Khan MA, Quiceno E, Ravinsky RA, Hussein A, Abdulla E, Nosova K, Moniakis A, Bauer IL, Pico A, Dholaria N, Deaver C, Barbagli G, Prim M, Baaj AA. Khan MA, et al. Spine Deform. 2024 May 9. doi: 10.1007/s43390-024-00892-1. Online ahead of print. Spine Deform. 2024. PMID: 38722532 Review.
Efficacy of long-term albumin therapy in the treatment of decompensated cirrhosis.
Khanna D, Kar P, Sahu P. Khanna D, et al. Indian J Gastroenterol. 2024 May 9. doi: 10.1007/s12664-024-01566-6. Online ahead of print. Indian J Gastroenterol. 2024. PMID: 38722510
METHOD: Study involved patients with Child B or C cirrhosis with an albumin level below 3.0 g/dL, who were administered 20% human albumin weekly with standard medical treatment (SMT) for three months or till serum albumin levels were 4.0 g/dL (whichever is earlier) and compared w …
METHOD: Study involved patients with Child B or C cirrhosis with an albumin level below 3.0 g/dL, who were administered 20% human albumin we …
Real-World Clinical Experience of Oral Semaglutide in a Secondary Diabetes Clinic in the UK: A Retrospective Observational Study.
Williams DM, Alberts BA, Sharaf A, Sharaf G, Bain SC, Kalhan A, Min T. Williams DM, et al. Diabetes Ther. 2024 May 9. doi: 10.1007/s13300-024-01590-x. Online ahead of print. Diabetes Ther. 2024. PMID: 38722497
We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice. METHODS: People with T2D initiated on oral semaglutide in secondary care diabetes clinics at two hospital sites in Wales (United Kingdom) were included. .. …
We aimed to determine the real-world impact of oral semaglutide on routinely collected clinical data in our practice. METHODS: People with T …
1,361,044 results
You have reached the last available page of results. Please see the User Guide for more information.